139 related articles for article (PubMed ID: 36099012)
21. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
[TBL] [Abstract][Full Text] [Related]
22. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children.
Kuhle S; Eulmesekian P; Kavanagh B; Massicotte P; Vegh P; Lau A; Mitchell LG
Haematologica; 2007 Apr; 92(4):554-7. PubMed ID: 17488668
[TBL] [Abstract][Full Text] [Related]
23. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
[TBL] [Abstract][Full Text] [Related]
24. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
[TBL] [Abstract][Full Text] [Related]
25. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
[TBL] [Abstract][Full Text] [Related]
26. The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin.
Korte W; Jovic R; Hollenstein M; Degiacomi P; Gautschi M; Ferrández A
Hamostaseologie; 2010 Nov; 30(4):212-6. PubMed ID: 21057708
[TBL] [Abstract][Full Text] [Related]
27. Monitoring of anticoagulant effects of direct thrombin inhibitors.
Fenyvesi T; Jörg I; Harenberg J
Semin Thromb Hemost; 2002 Aug; 28(4):361-8. PubMed ID: 12244483
[TBL] [Abstract][Full Text] [Related]
28. Monitoring of unfractionated heparin using activated partial thromboplastin time: an assessment of the current nomogram and analysis according to age.
Kim JS; Lee HJ; Sung JD; Kim HJ; Lee SY; Kim JS
Clin Appl Thromb Hemost; 2014 Oct; 20(7):723-8. PubMed ID: 23615295
[TBL] [Abstract][Full Text] [Related]
29. The monitoring of heparin administration by screening tests in experimental dogs.
Mischke R; Jacobs C
Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
[TBL] [Abstract][Full Text] [Related]
30. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
[TBL] [Abstract][Full Text] [Related]
31. Monitoring unfractionated heparin therapy in dogs by measuring thrombin generation.
Allegret V; Dunn M; Bédard C
Vet Clin Pathol; 2011 Mar; 40(1):24-31. PubMed ID: 21299582
[TBL] [Abstract][Full Text] [Related]
32. Monitoring heparin anticoagulation in the acute phase response.
Uprichard J; Manning RA; Laffan MA
Br J Haematol; 2010 May; 149(4):613-9. PubMed ID: 20230412
[TBL] [Abstract][Full Text] [Related]
33. Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy.
Byun JH; Jang IS; Kim JW; Koh EH
Blood Res; 2016 Sep; 51(3):171-174. PubMed ID: 27722127
[TBL] [Abstract][Full Text] [Related]
34. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
[TBL] [Abstract][Full Text] [Related]
35. A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.
Volovyk Z; Monroe DM; Qi Y; Becker R; Hoffman M
J Thromb Thrombolysis; 2009 Aug; 28(2):132-9. PubMed ID: 19543696
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
[TBL] [Abstract][Full Text] [Related]
37. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
[TBL] [Abstract][Full Text] [Related]
38. Monitoring unfractionated heparin in children: a parallel-cohort randomized controlled trial comparing 2 dose protocols.
Hanslik A; Kitzmüller E; Tran US; Thom K; Karapetian H; Prutsch N; Voitl J; Michel-Behnke I; Newall F; Male C
Blood; 2015 Oct; 126(18):2091-7. PubMed ID: 26239090
[TBL] [Abstract][Full Text] [Related]
39. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
[TBL] [Abstract][Full Text] [Related]
40. Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring.
Frugé KS; Lee YR
Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S90-7. PubMed ID: 26272899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
